Floatz logo

14 assets in Basal Cell Carcinoma

Therapeutic assets addressing Basal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Multiple Vitamins Injection
Basal Cell Carcinoma
Women's College HospitalP3BB (66)
Pembrolizumab
Basal Cell Carcinoma
Memorial Sloan Kettering Cancer CenterP1/2CCC (54)
Hydrogen Peroxide 30 % Topical
Basal Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP2CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Basal Cell Carcinoma
Regeneron PharmaceuticalsP2CCC (53)
Ipilimumab
Basal Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
Basal Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Mdna11
Basal Cell Carcinoma
Medicenna Therapeutics, Inc.P1/2CCC (48)
Oncolytic Virus Rp1
Basal Cell Carcinoma
Replimune, Inc.P1/2CCC (48)
Vidutolimod
Basal Cell Carcinoma
Regeneron PharmaceuticalsP2CC (45)
Cdx 1140
Basal Cell Carcinoma
University of Southern CaliforniaP1CC (43)
mq719
Basal Cell Carcinoma
Memorial Sloan Kettering Cancer CenterP1CC (43)
Recombinant Flt3 Ligand
Basal Cell Carcinoma
University of Southern CaliforniaP1CC (43)
Tocilizumab
Basal Cell Carcinoma
University of Southern CaliforniaP1CC (43)
r-5780
Basal Cell Carcinoma
Rise Therapeutics LLCP1NR ()